MAIA Biotechnology, Inc.
MAIA
$0.08
Change (1 day)
$5.99
Year High
$0.82
Year Low
Categories
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc. (MAIA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 144.68 K | -7,150,695 | 7.09 M | 7.57 M | 7.56 M |
| 2022 | 302.79 K | -10,950,927 | 3.51 M | 12.02 M | 11.81 M |
| 2021 | 43.67 K | -10,574,292 | 2.15 M | 11.33 M | 10.67 M |
| 2020 | -199,703 | 2.36 M | 746.51 K | 746.51 K | |
| 2019 | -1,674,393 | 409.74 K | 1.73 M | 1.73 M |